CD5 and neoplasm: The fact that treatment with itolizumab does not entirely deplete CD5 in immune cells favors the maintenance of resistance to death induced by the activation of tumor-specific T lymphocytes, which offers an advantage over conventional therapies specific against CD5 (50).